Apremilast useful in psoriatic arthritis Phoebe Starr writing in Value-based Care in
rheumatology reported an investigational oral drug, apremilast, was found to be effective
in a phase 3 clinical trial- the PALACE-1 study. It was effective in combination with
disease modifying anti-rheumatic drugs but was even more effective as a single agent.
The drug inhibits phosphodiestarase 4 and blocks inflammatory proteins while increasing
the amount of anti-inflammatory proteins. Safety was also acceptable. Both the 20 mg
and the 30 mg dose were statistically superior to placebo. Comment: Encouraging data for a drug that
appears to be specific for psoriatic arthritis.